News

Stay up to date on our
latest news and announcements.

News

Cytovation to present full safety and efficacy data from the CICILIA Phase I/IIa trial evaluating CY-101 in solid tumors at ESMO 2024

Cytovation appoints Olav Hellebø to its Board of Directors

Cytovation raises $8 million in Series A extension financing round for clinical advancement of CyPep-1, a first-in-class targeted tumor membrane immunotherapy

Cytovation appoints Iman Barilero as Chief Development Officer

Cytovation announces first patient dosed in Phase 2a study investigating CyPep-1 monotherapy in advanced melanoma refractory to checkpoint inhibitors

Cytovation presents Phase I dose escalation results at ESMO

Cytovation collaborates with Recurrent Respiratory Papillomatosis Foundation to expand its clinical investigations of CyPep-1 into rare neoplastic disease

Cytovation raises $20 million in Series A financing round to advance clinical development of CyPep-1, a first-in-class targeted tumor membrane immunotherapy